tumor infiltrating lymphocytes til therapies epidemiology forecast

Key Highlights

• TIL therapy represents a paradigm shift in solid-tumor immunotherapy, enabling effective targeting where CAR-T approaches have fallen short, expanding treatment options beyond PD-1 and BRAF/MEK inhibitors in metastatic melanoma, and supporting broad clinical exploration across NSCLC, HNSCC, CRC, pancreatic, prostate, cervical, and other.
• Prostate cancer represents the largest TIL therapy target, followed by NSCLC, driven not only by high incidence but also by extremely low immunogenicity, low response to checkpoint inhibitors, and limited effective post standard-of-care options, highlighting a significant unmet clinical opportunity.
• Tumors with high global incidence but low intrinsic immunogenicity (e.g., prostate, pancreatic cancers) present epidemiological mismatches where patient volume is high but TIL harvest success and expansion rates are low, constraining real-world scalability of TIL therapies.
• The complex manufacturing and infrastructure requirements of TIL therapy concentrate availability in high-resource settings, creating epidemiological inequities where regions with high cancer burden may have minimal access despite potential biological suitability.

DelveInsight’s “Tumor-infiltrating Lymphocytes (TIL) Therapies – Epidemiology Forecast – 2034” report delivers an in-depth understanding of TIL therapies, historical and forecasted epidemiology of TIL therapies in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020–2034

Tumor-infiltrating Lymphocytes (TIL) Therapies Overview  

Tumor-infiltrating Lymphocytes (TILs) are T cells that are resident within tumors. TILs represent a heterogeneous collection of T cells that can recognize a broad range of cancer-associated antigens, including patient-specific neoantigens. TILs derived from resected tumors can be cultured away from the immunosuppressive tumor microenvironment and expanded ex vivo. Adoptive Cell Therapy (ACT) with TILs involves the infusion of these massively expanded, unmodified autologous T cells as a personalized immunotherapy. Recent clinical advances have extended the application of TIL therapy beyond melanoma to other solid tumors, including NSCLC, HNSCC, cervical carcinoma, breast cancer, colorectal cancer, and osteosarcoma.

Mechanism of TIL Therapies

TIL therapy is an adoptive cell therapy that harnesses a patient’s own immune cells to target cancer. TILs are isolated from resected tumor tissue, expanded ex vivo with interleukin-2, and reinfused into the patient after lymphodepleting chemotherapy. These expanded T cells are enriched for tumor-reactive clones that recognize tumor-specific antigens, enabling direct cytotoxic killing of cancer cells and restoration of anti-tumor immune responses within the tumor microenvironment.

Tumor-infiltrating Lymphocytes (TIL) Therapies Epidemiology

The TIL therapies epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total cases of selected indications in the 7MM, Indication wise target patient pool of TIL therapies in the 7MM, and Indication wise treated cases of TIL therapies in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In 2024, the total cases of selected indication were 4,520,00 in the 7MM, which is anticipated to increase by 2034.
• In the 7MM, Prostate Cancer accounted for highest number of indication-wise eligible cases, i.e., 2,750,000 cases, in 2024. These cases are expected to increase during the study period (2020–2034).
• NSCLC had the second-highest number of incidence cases amongst the 7MM. Cervical cancer and endometrial cancer were the cancers with the least number of cases.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of TIL therapies, explaining its causes, mechanism, pathogenesis, and role in different solid tumors.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
• A detailed review of the TIL therapies epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Tumor-infiltrating Lymphocytes (TIL) Therapies Report Insights

• Patient Population
• Patient population by indication
• Country-wise Epidemiology Distribution

Tumor-infiltrating Lymphocytes (TIL) Therapies Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• TIL Therapies indication-wise Epidemiology Segmentation

Tumor-infiltrating Lymphocytes (TIL) Therapies Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs

• What are the disease risks and burdens of indication-wise epidemiology? What will be the growth opportunities across the 7MM with respect to the patient population about indication-wise epidemiology?
• What is the historical and forecasted indication-wise epidemiology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What is the incidence of indications across different underlying solid tumors for TIL therapies?
• What are the current gaps in epidemiological reporting, such as under-recognition or lack of published data?

Reasons to Buy

• Insights on patient burden/disease prevalence, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of treatment to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.